Ganoderic Acid A targeting <i>leucine‐rich repeat kinase 2</i> involved in Parkinson's disease–A computational study

Background Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's (AD). The exact mechanism behind PD still unknown and marked by symptoms like bradikynesia, tremors, walking or gait difficulties, etc. current medication used for levodopa, researchers are trying to develop a promising drug PD. In our study, we took Ganodema lucidium mushroom, known as “Reishi mushroom,” which has antioxidant, antiinflammatory, antihepatic properties, study five potent extracts, target Leucine-rich repeat kinase 2 (LRRK2) that involved in onset of Objective This aims find targeting LRRK2 Methods First ADMET analysis was performed compounds followed molecular docking each compound. Then, perform dynamics simulation all finally MMGBSA compounds. Results Based on result reach conclusion Ganoderic Acid A (GAA) compound LRRK2. Therefore, GAA needs further validation through vitro vivo studies.